Targeted Radiopharmaceutical Therapy for Bone Metastases

Area of Science:

• Nuclear medicine
• Oncology
• Radiopharmaceutical therapy

Background:

• Radiopharmaceuticals traditionally offered pain palliation for bone metastasis, primarily using beta emitters targeting bone matrix.
• Agents like radium-223 dichloride (223Ra) marked a paradigm shift, moving from palliation to treatment, especially in prostate cancer.

Purpose of the Study:

• To review the evolution of radiopharmaceutical therapy for bone metastasis.
• To highlight the impact of alpha emitters and targeted agents like 177Lu-PSMA.
• To emphasize the need for novel combination therapies.

Main Methods:

• Review of established radiopharmaceutical agents and their clinical use.
• Analysis of the impact of 223Ra-dichloride approval and survival benefits.
• Discussion of emerging targeted therapies and combination treatment strategies.

Main Results:

• Radiopharmaceuticals have a proven role in pain palliation and improving quality of life for bone metastasis.
• 223Ra-dichloride demonstrated survival benefits, leading to its predominant use in metastatic prostate cancer.
• Combination therapies, including those with 177Lu-PSMA, are increasingly applied.

Conclusions:

• The treatment of bone metastasis has evolved from palliation to therapeutic approaches using radiopharmaceuticals.
• Alpha emitters and targeted therapies represent significant advancements.
• Further exploration of combination therapies, including alpha and beta emitter cocktails, is crucial for expanding treatment options.